Published on Sat Jun 26 2021

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.

John Rubino, Diane E MacDougall, Lulu Ren Sterling, Stephanie E Kelly, James M McKenney, Narendra D Lalwani

PCSK9is lower low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. Bempedoic acid is an oral, once-daily, ATP-citrate lyase inhibitor.

1
4
18
Abstract

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) lower low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. However, some patients receiving PCSK9i therapy might require additional lipid-lowering therapy (LLT) to reach LDL-C goals. Bempedoic acid is an oral, once-daily, ATP-citrate lyase inhibitor that significantly lowers LDL-C in patients with hypercholesterolemia when given alone or as add-on therapy to statins and/or ezetimibe.